“…In addition, several studies have highlighted tumour budding (BD) and tumour-stroma ratio (TSR), considered in other non-TNM-based staging systems, as predictive factors for lymphatic diffusion and disease-free survival (DFS) 15,[45][46][47] . Table I shows the definition and purpose of these markers 2,15,37,38,42,45,46,[48][49][50][51][52][53][54][55][56][57] . To plan personalised treatment, oncologists need to assess these markers, including DOI, on biopsy samples according to the AJCC TNM (8th edition) recommendations 38 .…”